諾輝健康:常衞清香港首發售價3000港幣 在港籌建首個國際研發中心
格隆匯6月8日丨諾輝健康(6606.HK)攜手Prenetics Group Limited(PRE.US)今日在香港舉辦常衞清(ColoClear by Circle)產品上市發佈會。香港藝人,前奧運游泳運動員方力申宣佈擔任ColoClear by Circle在香港地區的宣傳大使。 常衞清在香港地區官方售價為3000港幣/份,目前已經進入當地最大的兩傢俬營醫療機構,EC Healthcare和Medifast。香港的腸鏡據公開信息在1萬港幣到2萬港幣區間。 Prenetics行政總裁兼聯合創始人楊聖武表示,常衞清是Prenetics今年兩個最重要管線產品之一,公司非常期待常衞清在香港市場的表現,複製大腸衞士(Cologuard)在美國的成功。他認為保險公司對常衞清的推廣至關重要,目前已經與各區域龍頭保險公司、各大醫院和政府開始探討合作。 諾輝健康CEO朱葉青宣佈公司正在香港籌建諾輝健康的首個國際研發中心,聚焦於包括二代測序技術(NGS)的多組學(multi-omics)癌症篩查技術創新和產品開發。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.